Discovery of P11–2: A Potent First-in-Class MNK1-Targeting PROTAC Degrader for the Treatment of Cancer

exhibited favorable PK profiles and robust antitumor effects in the xenograft model. These findings highlight the potential of P11-2 as a novel therapeutic strategy for targeting the degradation of MNK1.